問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of General Surgery

Division of General Internal Medicine

Division of Colorectal Surgery

Digestive System Department

更新時間：2024-05-30

蔣鋒帆CHIANG, FAN -FENG
  • Principal Investigator
  • Clinical Trial Experience (year)

  • hankel.chiang@gmail.com

Recruiting Trial

12Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蔣鋒帆

List

21Cases

2023-12-22 - 2030-10-25

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-11-30 - 2028-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2022-09-01 - 2027-08-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2025-10-01 - 2027-09-30

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2022-08-01 - 2027-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2018-04-01 - 2019-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Conventional Therapies but Have Not Failed Biologic Therapy

  • Condition/Disease

    Moderately to Severely Active Crohn's Disease

  • Test Drug

    Upadacitinib (ABT-494)

Participate Sites
4Sites

Recruiting3Sites

周仁偉
China Medical University Hospital-Taipei

未分科

2012-01-01 - 2014-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Study ended4Sites

2012-01-01 - 2015-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Study ended4Sites

2012-01-01 - 2013-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Study ended4Sites

2021-10-15 - 2022-06-09

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB